Acuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regenerationALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Acuitive Technologies® commercializes Citregraft™, with its first use in a surgical case, performed on November 4th, 2025.
Acuitive Technologies, Inc. Appoints Dr. Wayne Berberian as Chief Medical OfficerAcuitive Technologies announces the appointment of Dr. Wayne Berberian as Chief Medical Officer. In this role, Dr. Berberian will drive the company’s strategy behind new product development of first-in-class musculoskeletal tissue regenerative products that repair, restore and regenerate damaged or diseased tissue and improve patient outcomes.
Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™, A New Synthetic Bioactive Bone Void Filler for Orthopedic ProceduresALLENDALE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acuitive Technologies, Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CITREPORE, a unique synthetic bioactive bone void filler, using their patented CITREGEN® biomaterial technology. Following placement in a bony void, CITREPORE is resorbed predictably and replaced by the patient’s bone, providing Citrate to guide the healing process metabolically.
Acuitive Technologies Receives FDA 510(k) Clearance for CITRELOCK DUO a New Sports Medicine Fixation Device for Biceps Tenodesis and Tendon Transfer ProceduresALLENDALE, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Acuitive Technologies, Inc. (Acuitive) today announced the FDA 510(k) Clearance of CITRELOCK DUO Fixation Device for biceps tenodesis. The new fixation device provides surgeons a differentiated design via a tendon-friendly spiral thread featuring a next-generation resorbable technology, known as CITREGEN®, that has unique molecular and mechanical properties for orthopedic surgical applications.
Two Industry Veterans Join Acuitive Technologies, Inc. Board of Directors as Independent MembersALLENDALE, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Acuitive Technologies announced that Vince Forlenza and Gary Fischetti will join their Board of Directors. Both bring decades of medical technology experience and long track records of success. “We are honored these highly successful corporate leaders share our vision and enthusiasm and are willing to provide their guidance to help us deliver a truly market disruptive bio-regenerative platform for the benefit of patients,” said Alex Khowaylo, Acuitive’s Chairman of the Board. “We will benefit immediately from their insight and leadership as we move into our growth stage.”
